An inflammation-modulating ferroptotic nanoplatform for immune-compatible cancer therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Chronic inflammation hinders ferroptosis-based cancer therapies by impairing dendritic cell (DC) function.
• Oxidative stress intensification in ferroptosis strategies can exacerbate tumor inflammation.

Purpose of the Study:

• To develop an inflammation-compatible ferroptosis-inducing therapeutic platform.
• To overcome barriers in current ferroptosis-based cancer treatments.

Main Methods:

• Co-integration of celastrol (NF-κB modulator) with iron-coordinated mesoporous polydopamine (mPDA-Fe-Cel).
• Utilizing 808-nm photothermal heating and iron redox cycling for lipid peroxidation.
• Assessing inflammatory signaling, ferroptosis markers, and immunogenic cell death indicators.

Main Results:

• mPDA-Fe-Cel induced ferroptosis in tumor cells, increasing labile Fe²⁺, depleting glutathione, downregulating GPX4, and amplifying lipid peroxidation.
• The platform attenuated NF-κB inflammatory pathways, including CXCL8, TLR, and NLR signaling.
• Enhanced DC maturation, antigen presentation, and CD8⁺ T-cell infiltration were observed, leading to improved antitumor efficacy in murine models.

Conclusions:

• The developed nanoplatform effectively induces ferroptosis while modulating inflammation.
• This strategy creates an immune-permissive context for enhanced anti-tumor immune responses.
• The materials-based approach offers a promising avenue for immune-compatible cancer nanotherapy.